Liminatus Pharma (NASDAQ:LIMN) Stock Jumps 7.9% – Time to Buy?

Liminatus Pharma Inc. (NASDAQ:LIMN – Get Free Report)’s share price shot up 7.9% on Friday. The company traded as high as $2.99 and last traded at $2.99. Approximately 13,582 shares changed hands during trading, a decline of 58% from the average daily volume of 32,036 shares. The stock had previously closed at $2.77.

Analysts Set New Price Targets

Several brokerages have recently issued reports on LIMN. Weiss Ratings cut Liminatus Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, September 3rd. Wall Street Zen lowered shares of Liminatus Pharma to a “strong sell” rating in a report on Saturday, August 22nd. One investment analyst has rated the stock with a Sell rating. According to MarketBeat, Liminatus Pharma has an average rating of “Sell”.

View Our Latest Research Report on Liminatus Pharma

Liminatus Pharma Price Performance

The business has a 50-day simple moving average of $3.36 and a 200-day simple moving average of $9.66. The firm has a market capitalization of $4.02 million, a PE ratio of -0.13 and a beta of 4.89.

About Liminatus Pharma

(Get Free Report)

Liminatus Pharma, Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.

Recommended Stories

Receive News & Ratings for Liminatus Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liminatus Pharma and related companies with MarketBeat.com's FREE daily email newsletter.